Angiogenesis

print version

Angiotox logo

AngioTox: Histopathologic & Mechanistic Assessment of Angiogenesis Inhibitor Related Toxicities: A Cross-Sectoral, Multi-disciplinary Approach

EU Flag, Marie Curie Actions Logo

A Marie Curie Industry-Academia Partnerships and Pathways funded programme.

 

Inhibition of angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a well established therapeutic strategy against cancer. Inhibitors of angiogenesis have been developed to block tumour growth and metastasis, and a number of these inhibitors are now clinically approved. However, contrary to initial expectations, angiogenesis inhibitors can cause a range of toxicities in patients.

The tumor angiogenesis process and therapeutic role of angiogenesis inhibitors

AngioTox is an EU funded cross-sectoral collaboration in the field of biomedicine, responding to a pressing need to understand mechanisms of toxicity associated with angiogenesis inhibitor treatment. AngioTox is comprised of academic groups, SMEs (including OncoMark), a global pharmaceutical leader in angiogenesis inhibitor development (F. Hoffman La Roche), and a large company concerned with monitoring drug modulation of cellular pathways. The goal of this consortium is to facilitate comprehensive histopathologic and mechanistic assessment of angiogenesis inhibitor related toxicities following treatment with the two main class of angiogenesis inhibitor; monoclonal antibodies and tyrosine kinase inhibitors.

AngioTox website

AngioPredict will identify biomarkers to predict whether individual metastatic colorectal cancer patients will respond positively to AvastinĀ® combination therapy. This will prevent unnecessary treatment, save critical time in patient care and improve quality of life.

AngioPredict is an FP7-funded research project which has secured approximately €6 million in competitive non-exchequer funding. The project will work towards providing personalised medicine for patients with metastatic colorectal cancer. 

AngioPredict will identify biomarkers to predict whether individual metastatic colorectal cancer patients will respond positively to AvastinĀ® combination therapy. This will prevent unnecessary treatment, save critical time in patient care and improve quality of life. 

AngioPredict website

Back to Research